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Abstract
The inflammatory bowel disease (IBD) is associated with different neurological and psychi-
atric disorders, which are integrated among the extra-intestinal manifestation of this dis-
ease. The physiopathology of neurological manifestations of IBD varies among the different 
kind of complications. The origin and the significance of these manifestations must be 
understood by clinicians who manage IBD patients. Some of them are related to therapeu-
tic agents. The present chapter consists of a review of the most prevalent neurological and 
psychiatric disorders associated with IBD. The physiopathology of those entities will also 
be discussed, as well as the appropriate management for their prevention and treatment.
Keywords: neurological disorders, psychiatric disorders, thrombosis, demyelination, 
peripheral neuropathy, extra-intestinal manifestations
1. Introduction
Inflammatory bowel disease (IBD) is a chronic disease of the gastrointestinal tract with an 
unknown etiology, which alternates between periods of symptoms relapse and remission 
[1, 2]. IBD involves various entities. Crohn’s disease (CD) and ulcerative colitis (UC) are 
the most common, but other inflammatory conditions of the gastrointestinal tract are also 
included under this term, such as the indeterminate colitis, microscopic colitis and pouchitis 
[3]. In the present chapter, only CD and UC are discussed.
The incidence of IBD is different depending on its two main forms. CD is diagnosed in 
0.5–10.6 patients/100,000 inhabitants/year, while the global incidence of UC is estimated at 
0.9–24.3 patients/100,000 inhabitants/year. There is some evidence about the increase of these 
incidence figures in the past 10 years [2]. On the other hand, the prevalence of CD in European 
countries ranges from 1.5 to 213 cases per 100,000 people and the prevalence of UC ranges 
from 2.4 to 294 cases per 100,000 people [2].
© 2018 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
IBD consists of an inflammation of the bowel, with different extension and histological fea-
tures between CD and UC. However, this disease does not only involve the gastrointestinal 
tract, but there is also a long list of extraintestinal manifestations that can emerge prior to or 
during the disease. The most frequent ones are those involving the skin (dermatological), the 
joints (rheumatological), the eyes (ophthalmological), the liver and/or the biliary tract and the 
genitourinary area (gynecological and/or urological). The prevalence of at least one extraint-
estinal manifestation varies from 6.2 to 46.6% [4].
Neurological manifestations of IBD are unusual, but they are potentially harmful, lead-
ing to severe and irreversible consequences if they are not detected and managed early 
and properly. The prevalence of neurological manifestations has not been appropriately 
established, but some authors have reported a prevalence of 20–30%, although there is a 
general belief that subclinical or unrecognized neurological impairment may be present in 
IBD patients [4–6].
The aim of the present chapter is to briefly review the main neurological manifestations asso-
ciated with IBD, with a special focus on their physiopathological mechanisms.
2. General pathophysiological considerations of IBD and its 
neurological manifestations
Although a specific etiological agent in the development of IBD has not been established, it is 
widely accepted that some scenarios may be associated with the development of this disease [4]:
• An inflammatory reaction to a persistent bowel infection.
• The presence of defects in the barrier of the intestinal mucosa to act against certain antigens.
• The presence of disturbances in the immune response to certain antigens.
In this regard, a dysfunction of the immune system and a chronic inflammatory response 
appear both in the context of a specific environmental situation and in a genetically predis-
posed patient [1]. However, bearing in mind the physiopathology of neurological manifesta-
tions, there are different mechanisms that may specifically be involved in their development [4]:
• Malabsorption and secondary deficit of vitamins (mainly vitamin B12), which are essential 
for myelin maintenance and regeneration [7].
• Hypercoagulability state, related to a chronic inflammatory response that may lead to isch-
emic events.
• Formation of metabolic toxic agents in the damaged bowel.
• Immunological disturbances that may lead to autoimmune response against glial-neural 
components.
• Opportunistic infections secondary to the impairment of the immune system or because of 
the treatment for IBD.
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These mechanisms can lead to neurological damage acting individually or in combination. 
The identification of the leading mechanism is essential to prevent greater neurological dam-
age. Unfortunately, in many cases, it is not possible to identify the main pathological factor.
Nevertheless, disease-related mechanisms are not the only ones that need to be considered 
to understand the origin of neurological manifestations. The pharmacological agents usu-
ally used in IBD may also lead to the development of such manifestations. The appropriate 
selection of a therapeutic agent depends on the subtype of disease (CD or UC), location and 
phenotype of the disease [8].
Some of these treatments try to prevent new relapses of the disease, whereas others try to 
control the symptoms during a relapse. The vast majority of these therapeutic agents can 
produce neurological manifestations as an adverse effect (Table 1), thus clinicians always 
have to consider the possibility that neurological manifestations in IBD patients may have a 
pharmacological rather than a primary IBD-related origin.
Drug category High frequency 
(>1 case per 100 
patients)
Low frequency 
(>1 case per 1000 
patients)
Rare (>1 case per 
10,000 patients)
Unknown  
frequency
Steroids Seizures. 
Development 
or worsening 
of psychiatric 
disorders 
(euphoria, mood 
and personality 
changes, depression 
and psychosis)
Dizziness, headache, 
insomnia
5-Aminosalicilates Headache, 
dizziness and 
peripheral 
neuropathy
Antibiotics Metronidazole Seizures, peripheral neuropathy. Others: dizziness, ataxia, incoordination, 
confusion, irritability depression, weakness, insomnia and encephalopathy
Ciprofloxacin Headache, 
dizziness, sleep 
disorders, taste 
disorders, motor 
hyperactivity
Sensitive 
disturbances, 
tremor, seizures, 
migraine, 
incoordination, 
olfactory disorders, 
confusion, anxiety, 
depression, 
psychotic reactions
Peripheral neuropathy
Ciclosporin A Tremor, 
headache, 
seizures, 
paresthesia
Encephalopathy, 
confusion, 
disorientation, 
decrease level 
consciousness, 
anxiety, 
insomnia, visual 
disturbances, 
cortical blindness, 
comma, paresia 
and ataxia
Motor 
polyneuropathy, 
optic nerve edema
Migraine
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Methotrexate Paresthesia Motor weakness, 
encephalopathy, 
seizures and 
headache
Mood disorders 
and cognitive 
disturbances. 
Motor weakness, 
aphasia, cranial 
nerve disturbances
Intracranial 
hypertension, 
neurotoxicity, 
arachnoiditis, 
paraplegia, 
astonishment, ataxia, 
dementia, dizziness
Thiopurines Azathioprine Myasthenic 
crisis, paresia, 
polyneuritis
Progressive multifocal 
leucoencephalopathy 
when other 
immunosuppressors  
are combined
6-Mercaptopurine Not reported
Anti-TNF Infliximab Headache, 
dizziness
Depression, 
confusion, 
amnesia, 
anxiety apathy, 
drowsiness. 
Demyelinating 
disease 
exacerbation
Adalimumab Mood changes 
(depression), 
anxiety, 
insomnia. 
Headache, 
paresthesias, 
migraine, 
radicular 
compression
Cerebrovascular 
accident, tremor, 
neuropathy
Multiple sclerosis 
and other 
myelinating 
disorders (optic 
neuritis and 
Guillain-Barré 
syndrome)
Certolizumab 
pegol
Demyelinating 
disease, including 
multiple 
sclerosis (onset 
or exacerbation). 
Seizures, peripheral 
neuropathy
Golimumab Dizziness, 
headache, 
paresthesias. 
Depression, 
insomnia
Instability Multiple sclerosis 
and other 
demyelinating 
diseases, dysgeusia
Vedolizumab Headache, 
paresthesia
Ustekinumab Dizziness, 
headache
Depression. 
Facial palsy
Table 1. IBD treatment-related neurological complications with categorization of their frequency.
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3. Venous and arterial thrombotic and thromboembolic manifestations
Thromboembolic events are common in the context of IBD, secondary to the hypercoagulabil-
ity state that exists in this disease. This hypercoagulability is associated with an increase of 
coagulation-associated factors and thrombin levels, as well as fibrin formation; a decrease of 
natural anticoagulant factors; a decrease in fibrinolytic activity; the presence of endothelial 
anomalies; and an increase in the count and activity of platelets [9].
Overall, the incidence of thrombotic complications is 1.2–7.5% in clinical studies, but this can 
rise to 39% when post-mortem studies are considered [10, 11]. Both arterial and venous sys-
tem may be affected, but deep venous thrombosis and pulmonary thromboembolism are the 
most common thromboembolic complications in IBD [10–13].
Intracranial thromboembolic events are much less frequent. Cerebral venous thrombosis is 
more common in CU than in CD, and this may involve superficial or deep cerebral venous 
systems or even some of the brain venous sinus [11, 14]. The risk of thrombotic or thrombo-
embolic complications in the brain is clearly associated with the activity of the disease. During 
these periods, IBD patients have a higher risk of cerebral thromboembolic complications than 
the normal population [9, 10]. These events are rarely reported during periods of non-activity 
of the disease [9, 10], although some authors have described a higher incidence of thrombo-
embolic events in IBD patients than in healthy controls not only during a relapse of the dis-
ease but also during remission periods [15]. Larger cohort and case-control studies are needed 
to confirm this finding, because if IBD patients suffer more thromboembolic events even dur-
ing remission periods, anticoagulant therapies might be routinely indicated.
In any case, the increase of thromboembolic events during relapses is clearly related to the 
inflammatory response whose effect in the coagulation and platelet system has been described 
above. Nevertheless, the use of steroids, dehydration, the increase of homocysteine and infec-
tions (all of which are associated with relapsing periods) may also contribute to the devel-
opment of thrombotic complications [10–13, 16]. Furthermore, the presence of mutations in 
Leiden factor V in IBD patients leads to a higher incidence of thrombotic events [17].
Therefore, bearing in mind the high risk of thromboembolic events in IBD patients, mostly 
during relapses [18, 19], it is essential to rapidly initiate a primary prophylaxis, with an early 
mobilization, a correct rehydration and vitamin reposition, as well as the use of prophylactic 
anticoagulants (mainly low molecular weight heparins). All of these measures are proven to 
be useful in the prevention of venous thromboembolic events [20].
On the other hand, IBD patients also seem to present a higher incidence of arterial thrombo-
embolic events. Indeed, many studies have reported an association between cardiovascular 
events and other chronic inflammatory diseases, like rheumatoid arthritis, lupus or psoriasis 
[21–23]. Active IBD is also associated with a higher risk of cardiovascular events (spontaneous 
or after surgical/invasive procedures), especially in young female patients [9].
When arterial thromboembolic events occur in the brain, they can be classified as ischemic 
stroke. Although the literature agrees about the high risk of thromboembolic events in IBD 
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patients, the increase in the incidence of ischemic stroke in IBD patients is a matter of debate 
[9]. In this regard, Huang et al. [24], in a large retrospective cohort study, analyzed the risk of 
ischemic stroke in IBD patients of a Taiwanese population. Although the studied groups were 
not completely comparable in demographical and comorbidity features, the authors reported 
a higher prevalence of ischemic stroke in IBD patients (mainly in CD patients) than the general 
population (hazard ratios for UC and CD were 1.01 [95% confidence interval = 0.84–1.21] and 
1.15 [95% confidence interval = 1.04–1.28], respectively) [24]. Similar results were reported in a 
Danish population-based setting (also with a mismatch in comorbidity distribution), showing 
a relative risk (RR) of 1.15 of suffering ischemic stroke in an IBD population (95% confidence 
interval 1.04–1.27) of suffering ischemic stroke in an IBD population [25]. Therefore, there is 
weak evidence of the higher incidence of ischemic stroke in IBD populations. In any case, it 
seems to be of the utmost importance to manage cardiovascular risk factors in IBD patients 
[9]. Their combination with the pro-thrombotic situation that may be present in any phase 
of IBD can play a major role in the development of brain ischemic complications, which are 
associated with a high level of dependence and an important worsening of quality of life.
However, vascular events may not be only associated with pro-thrombotic conditions. 
Vasculitis may also contribute to the presence of neurological manifestations. Bearing this in 
mind, systemic vasculitis is also considered an extra-intestinal manifestation of IBD. Wegener’s 
granulomatosis, Takayasu arteritis, medial temporal arteritis and Cogan’s syndrome (among 
others) have been reported in combination with IBD [4, 26]. For example, Takayasu arteritis is 
associated with IBD in 9.6% of cases [27], and this frequency seems to be higher in CD patients 
(9%) [28] than in UC (6.4%) [29]. The pathogenesis of vasculitis associated with IBD is mediated 
by immune complex deposits and cytotoxic lymphocytes [30]. The vasculitis of IBD patients 
involves medium and large caliber vessels and may lead to brain ischemic events [4], and some 
of them can directly affect the central nervous system (CNS) [31]. The global frequency of vas-
culitis associated with IBD is unknown, but it has been reported that such cases of vasculitis 
involving the CNS are rare [31]. Furthermore, this manifestation seems to be independent of the 
activity of the disease in the gastrointestinal tract [30, 32]. A correct diagnosis of CNS vasculitis 
is essential, because it allows the initiation of the appropriate treatment and the prevention of 
significant neurological impairment. Thus, when IBD patients present any CNS vascular event, 
vasculitis must be considered as a possible diagnosis and it has to be appropriately ruled out.
4. Demyelinating diseases
The association of demyelinating diseases has been proposed since the early 1980s. Rang et al. 
described a higher prevalence of multiple sclerosis (MS) than expected in UC patients [33]. 
Subsequently, this finding has been confirmed by many reports, but not only for UC but also 
for CD [34–36]. For instance, Gupta et al. described an increased risk of optic neuritis and 
other forms of MS in CD (odds ratio = 1.54) and UC (odds ratio = 1.75) [35]. In the same line, a 
recent meta-analysis concluded that IBD patients present a higher risk of suffering from con-
comitant MS and vice versa (i.e. MS patients have a higher risk of suffering from associated 
IBD) [36]. These authors found an increased risk of 50% [36].
However, some authors have proposed that the development of demyelinating diseases in IBD 
patients is more related to the use of anti-TNFα drugs [37]. In this regard, the Spanish registry 
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of autoimmune adverse events of biological agents (BIOGEAS Project) reported 12 cases of 
MS and 25 cases of optic neuritis in IBD patients treated with anti-TNFα [38]. Furthermore, 
this phenomenon is not exclusive to IBD patients. Arthritis patients treated with anti-TNFα 
agents may develop MS or demyelinating lesions, with a partial or complete resolution of 
neurological symptoms after discontinuing the medication [39]. An increased number of new 
white matter lesions and new relapses have also been reported in MS patients treated with 
infliximab [40]. On the other hand, the use of Natalizumab, a monoclonal antibody against 
alfa4-integrin used in some cases of IBD, is associated with progressive multifocal leukoen-
cephalopathy (PML). This disease appears after a reactivation of the JC virus infection, and the 
use of Natalizumab is clearly associated with this reactivation. PML is associated with a bad 
prognosis with a mortality rate at 6 months above 60% [37].
Apart from demyelinating diseases associated with IBD, there is strong evidence of a higher 
prevalence of white matter lesions in neurologically asymptomatic IBD patients than in 
healthy subjects [5, 41]. Although these lesions are usually asymptomatic, their number and 
volume tend to increase with age (mostly in CU patients) [41]. In any case, whenever these 
lesions become symptomatic, their association with other CNS complications (e.g. cerebro-
vascular complications) has to be identified.
Therefore, in spite of the plausible relationship between MS and IBD, the presence of white 
matter lesions is not evidence of the coexistence of both diseases. In fact, most of these lesions 
have no clinical relevance and their presence in IBD patients should not be used to infer active 
CNS disease [42]. Further research is needed about the origin of these lesions and their neuro-
logical and cognitive consequences in IBD patients.
5. Epilepsy
The relationship between epilepsy and IBD is uncertain. Lossos et al. reported a prevalence of 
1.9% in a cohort of 638 IBD patients, although the majority of these patients had a structural 
and/or metabolic cause that may lead to epileptic seizures [32]. Other authors have reported 
an improvement of seizures in CD patients after treatment initiation, suggesting that immu-
nological mechanisms may be associated with the development of this disorder [43]. This 
finding might also be supported by some case reports [44].
However, the most plausible explanation for the development of epileptic seizures in IBD 
patients is that other CNS complications (e.g. thromboembolic events or unspecific white mat-
ter lesions) or other systemic complications (e.g. dehydration, low levels of magnesium, etc.) 
may facilitate its development [45, 46]. Because of the above, a correct therapeutic manage-
ment may help to resolve and/or prevent this condition.
6. Peripheral neuropathy
Peripheral neuropathy (PN) is one of the most common neurological complications in 
IBD patients [32, 43, 47]. Many factors have been associated with the development of PN, 
such as extraintestinal inflammation, immunological phenomena, nutritional disturbances 
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(e.g.  malabsorption-related vitamin deficit) and adverse effects of IBD therapeutic agents 
(e.g. metronidazole or anti-TNF agents) [48–50]. Whenever these causes are ruled out, the 
frequency of PN in IBD patients varies from 0 to 39% [51].
IBD-associated PN may be associated with axonal damage or demyelination and it may have 
an acute or chronic presentation [47, 51]. Cases of mononeuropathy, plexopathies, multiple 
mononeuritis, compressive neuropathies and cranial neuropathies have also been reported 
[50]. Bearing this in mind, IBD-related PNs present great clinical variability, although there is 
a certain dominance of non-demyelinating vs. myelinating forms [48].
Demyelinating forms have a better prognosis than non-demyelinating forms, because they 
have a more favorable response to immunotherapy. This situation may be related to the role 
that T lymphocytes seem to play in demyelinating IBD-associated PNs. On the other hand, 
the relationship between axonal PNs and immunological disturbances is less clear [47, 48].
7. Psychiatric disorders
IBD patients show a high prevalence of psychiatric disorders, with depression and anxiety as 
the main diagnosis [1, 52, 53]. The prevalence of depression in IBD patients varies from 15 to 
30%, but the frequency of anxiety rises to 80%, mainly associated with the relapses of the dis-
ease [54, 55]. There is no overall difference in the frequency of psychiatric disorders between 
UC and CD [52].
Several factors have been associated with IBD-related depression: female gender, active intes-
tinal disease, the presence of fistulas or perianal disease, use of biological treatments and the 
necessity of surgery because of IBD [55]. On the other hand, IBD patients with IBD seem to 
present more aggressive phenotypes of the disease, with more relapses and shorter periods of 
remission [52]. In any case, the prevalence of depression or anxiety is even higher when other 
psychiatric conditions coexist [1, 52, 53].
Anyway, depression and anxiety are not the only IBD- associated psychiatric disorders. The 
Manitoba IBD Cohort Study reported a higher prevalence in IBD patients than in general popula-
tion of panic and obsessive-compulsive disorders [56]. Controversy exists around bipolar disorder. 
On the one hand, the Manitoba IBD Cohort Study reported a lower prevalence of bipolar disorder 
in IBD than in the general population. On the other hand, Eaton et al. (2010) reported a higher 
frequency of this psychiatric condition in IBD patients, more specifically in CD patients [57].
However, it is widely accepted that there is an infra-diagnosis and infra-treatment of psy-
chiatric disorders, with no systematic screening established in clinical guidelines. There is a 
strong evidence of the presence of a bidirectional relationship between the degree of inflam-
mation in the gastrointestinal tract and the development of depression. This can be explained 
by the brain-gut axis hypothesis. The brain and the gut are communicated by the autonomic 
nervous system (sympathetic and parasympathetic systems). The vagus nerve (the main para-
sympathetic afferent) transmits information to the CNS about luminal osmolarity, carbohy-
drate levels, mechanical distortion of the mucosa and the presence of bacterial or cytostatic 
drugs. On the other hand, sympathetic afferents transmit visceral pain [58].
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Information sent by the gastrointestinal system reaches the medulla (nucleus tractus solitar-
ius) and travels upstream until it reaches the paraventricular nucleus where it finally modu-
lates the hypothalamic–pituitary–adrenal (HPA) axis [59].
Some authors proposed that an impairment in the gut-brain axis can be induced by stress. In 
this regard, stressful situations lead to a vagal inhibition and an overactivation of the sympa-
thetic system. These conditions associated with other CNS-mediated responses involving the 
modulation of the immune system and the HPA axis may be associated with the appearance 
of a gastrointestinal immunoinflammatory response [58, 60]. For instance, during depression, 
an elevation of alpha-TNF, IL-1, reactive C protein and haptoglobin and a decrease of IL-10, 
TGF-B, albumin and transferrin are observed [61].
Therefore, there is a notable association between IBD and psychiatric disorders. New studies 
are necessary to elucidate in which cases the psychiatric condition is the cause or the conse-
quence of IBD. This may help to understand pathophysiological aspects of IBD that are still 
unknown and ultimately may allow better management of the disease.
8. Conclusion
IBD patients may suffer from different neurological manifestations during their disease. The 
pathophysiological mechanisms involved in these complications are variable and, in many 
cases, they are still unrecognized. Anyway, clinicians must stay focused on the early identi-
fication of IBD neurological complications and to rapidly establish the appropriate manage-
ment to prevent further impairment.
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